原著論文（英文）
Original Articles
105. Kashiwagi, H., Sato, Y., Nashimoto, S., Imai, S., Takekuma, Y., Sugawara,
M., Platelets affect the activity of amino acid transporter SNAT4 in HuH-7
human hepatoma cells, Biol pharm bull. 47(3), 652-659, 2024. https://doi.org/10.1248/bpb.b23-00904
104.Nashimoto, S., Miyamae, M., Higuchi, I., Kono, M., Tada, M., Atsumi, T., Sugawara, M., Takekuma, Y., Decrease in mycophenolic acid plasma level by sacubitril/valsartan in a lupus nephritis patient: A case report, Case Rep Nephrol Dial, 14, 30-35, 2024. https://doi.org/10.1159/000536468
103.Tsutsumi, T., Imai, S., Momo, K., Kashiwagi, H., Sato, Y., Sugawara,
M., Takekuma, Y., Comparison of the incidence of nausea and vomiting between
linezolid and vancomycin using claims database: a retrospective cohort
study, Int J Clin Pharm. Online ahead of print. https://doi.org/10.1007/s11096-023-01668-9
102.Kaburaki, S., Imai, S., Kashiwagi, H., Sato, Y., Sugawara, M., Takekuma
Y., Effects of body composition on renal function estimates in older patients,
Biol pharm bull. 46(11), 1609-1618, 2023. https://doi.org/10.1248/bpb.b23-00466
101. Inoue, Y., Sato, Y., Kashiwagi, H., Nashimoto, S., Sugawara, M., Takekuma,
Y., Monitoring Salivary Concentrations of Tedizolid and Linezolid Using
Rats, Eur J Drug Metab Pharmacokinet, 48(4), 387-395, 2023. https://doi.org/10.1007/s13318-023-00836-6
100. Miyai, T., Takekuma, Y., Kashiwagi, H., Sato, Y., Nashimoto, S., Sugawara, M., Imai, S., Risk Factor Analysis of Vancomycin-Induced Nephrotoxicity in Paediatric Patients Aged 0–1 Year Using Japanese Medical Database, Biol pharm bull, 46(6), 817-823, 2023. https://doi.org/10.1248/bpb.b23-00013
99. Inoue, Y., Takekuma, Y., Miyai, T., Kashiwagi, H., Sato, Y., Sugawara, M., Imai, S., Use of Japanese big data from electronic medical records to investigate risk factors and identify their high-risk combinations for linezolid-induced thrombocytopenia, Eur J Clin Pharmacol, 79(3), 415-425, 2023. https://doi.org/10.1007/s00228-023-03455-x
98. Nashimoto, S., Imai, S., Sugawara, M., Takekuma, Y., Usefulness of the albumin–bilirubin score in determining the initial dose of voriconazole for patients with liver cirrhosis, Biol pharm bull, 46(2), 230-236, 2023. https://doi.org/10.1248/bpb.b22-00608
97. Kadomura, S., Imai, S., Momo, K., Sato, Y., Kashiwagi, H., Itoh, T., Sugawara, M., Takekuma, Y., Effects of piperacillin/tazobactam or cefepime on folinate dose in patients receiving high-dose methotrexate: a retrospective cohort study using Japanese administrative claims data, J Oncol Pharm Pract, 28(7), 1534-1542, 2022. https://doi.org/10.1177/10781552211034703
96. Miyai, T., Imai S., Yoshimura, E., Kashiwagi, H., Sato, Y., Ueno, H., Takekuma, Y., Sugawara, M., Machine learning-based model for estimating vancomycin maintenance dose to target the area under the concentration curve of 400-600 mg・h/L in Japanese patients, Biol pharm bull, 45(9), 1332-1339, 2022. 10.1248/bpb.b22-00305
95. Imai, S., Kadomura, S., Miyai, T., Kashiwagi, H., Sato, Y., Sugawara, M., Takekuma, Y., Using Japanese big data to investigate novel factors and their high-risk combinations that affect vancomycin-induced nephrotoxicity, Br J Clin Pharmacol, 88(7), 3241-3255, 2022. https://doi.org/10.1111/bcp.15252
94. Kaburaki, S., Yoshimura, E., Miyamoto, Y., Imai, S., Kashiwagi, H., Ueno, H., Sugawara, M., Takekuma, Y., Hepatic drug metabolism in older people with body composition changes, Geriatr Gerontol Int, 22(5), 449-454, 2022. https://doi.org/10.1111/ggi.14380
93. Sato, Y., Takekuma, Y., Daisho, T., Kashiwagi, H., Imai, S., Sugawara, M., Development of a method of liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of linezolid and tedizolid in human plasma, Biol pharm bull, 45(4), 421-428, 2022. https://doi.org/10.1248/bpb.b21-00798
92. Imai, S., Kashiwagi, H., Sato, Y., Miyai, T., Sugawara, M., Takekuma, Y., Factors affecting creatine phosphokinase elevation during daptomycin therapy using combination of machine learning and conventional methods, Br J Clin Pharmacol, 88(3), 1211-1222, 2022. https://doi.org/10.1111/bcp.15063[Press release]
91. Tsutsumi, T., Imai, S., Kashiwagi, H., Sato, Y., Sugawara, M., Takekuma, Y., Investigation of the Risk Factors of Vomiting during Linezolid Therapy: A Retrospective Observational Study, Eur J Clin Pharmacol, 78(2), 279-286, 2022. https://doi.org/10.1007/s00228-021-03221-x
90. Imai, S., Momo, K., Kashiwagi, H., Sato, Y., Miyai, T., Sugawara, M., Takekuma, Y., Prescription and therapeutic drug monitoring status of valproic acid among patients receiving carbapenem antibiotics: A preliminary survey using a Japanese claims database, Annals of Clinical Epidemiology, 4(1). 6-10, 2022. https://doi.org/10.37737/ace.22002
89. Imai, S., Momo, K., Kashiwagi, H., Sato, Y., Miyai, T., Sugawara, M., Takekuma, Y., A cross-sectional survey of hospitalization and blood tests implementation status in patients who received tolvaptan under 75 years of age using a Japanese claims database, Expert Opin Drug Saf, 20(10), 1257-1266, 2021. doi: 10.1080/14740338.2021.1951219
88. Imai, S., Nasuhara, Y., Momo, K., Oki, H., Kashiwagi, H., Sato, Y., Miyai, T., Sugawara, M., Takekuma, Y., Implementation status of liver function tests for monitoring benzbromarone-induced hepatotoxicity: An epidemiological survey using the Japanese claims database, Biol pharm bull, 40(10), 1499-1505, 2021. https://doi.org/10.1248/bpb.b21-00393
87. Yamashita, S., Imai, S., Momo, K., Kashiwagi, H., Sato, Y., Sugawara, M., Takekuma, Y., Investigation of the real-world situation and risk factors associated with olanzapine prescribed to diabetes patients by using a Japanese claims database, Biol pharm bull, 44(8), 1151-1155, 2021.https://doi.org/10.1248/bpb.b21-00170
86. Aoyama, T., Kuriyama, H., Sato, Y., Imai, S., Kashiwagi, H., Sugawara, M., Takakuma, Y., cAMP signaling pathway prevents dasatinib-induced vascular hyperpermeability, Biol pharm bull, 44(8), 1101-1110, 2021. https://doi.org/10.1248/bpb.b21-00270
85. Imai, S., Momo, K., Kashiwagi, H., Miyai, T., Sugawara, M., Takekuma, Y., Probiotic prescription status of pediatric patients with otitis media receiving oral amoxicillin or amoxicillin/clavulanate from April 2016 to March 2017 using a Japanese health insurance claims database, Biol pharm bull, 44(3), 448-452, 2021. https://doi.org/10.1248/bpb.b20-00214
84. Nashimoto, S., Yagi, S., Takeda, N., Nonaka, M., Takekuma, Y., Sugawara, M., Sato, Y., A new system to evaluate characteristics of Niemann-Pick C1 Like 1-mediated cholesterol transport using Xenopus laevis oocytes, Biochim. Biophys. Acta Biomembr, 1863, 183508, 2021.https://doi.org/10.1016/j.bbamem.2020.183508
83. Sato, Y., Yamaguchi, K., Ogawa, M., Takekuma, Y., Sugawara, M., An imaging approach for determining the mechanism of enhancement of intestinal absorption of an L-theanine supplement, PLoS ONE, 16, e0253066, 2021. https://doi.org/10.1371/journal.pone.0253066
82. Miyai, T., Imai S., Kashiwagi, H., Sato, Y., Kadomura, S., Yoshida, K., Yoshimura, E., Teraya, T., Tsujimoto, T., Kawamoto, Y., Itoh, T., Ueno, H., Goto, Y., Takekuma, Y., Sugawara M., A risk prediction flowchart of vancomycin-induced acute kidney injury to use when starting vancomycin administration: a multicenter retrospective study, Antibiotics (Basel), 9(12), 920, 2020. https://doi.org/10.3390/antibiotics9120920
81. Imai, S., Kadomura, S., Momo, K., Kashiwagi, H., Sato, Y., Miyai, T., Sugawara, M., Takekuma, Y., Comparison of interactions between warfarin and cephalosporins with and without the N-methyl-thio-tetrazole side chain, J Infect Chemother, 26(11), 1224-1228, 2020. https://doi.org/10.1016/j.jiac.2020.07.014
80. Imai, S., Momo, K., Kashiwagi, H., Miyai, T., Sugawara, M., Takekuma, Y., A cross-sectional exploratory survey on occurrence of triple-whammy prescription pattern in Japan, Int J Clin Pharm, 42(5), 1369-1373, 2020. 10.1007/s11096-020-01088-z
79. Imai, S., Momo, K., Kashiwagi, H., Miyai, T., Sugawara, M., Takekuma, Y., Prescription of colchicine with other dangerous concomitant medications: A nation-wide survey using the Japanese claims database, Biol pharm bull, 43(10), 1519-1525, 2020. https://doi.org/10.1248/bpb.b20-00314
78. Imai, S., Momo, K., Kashiwagi, H., Miyai, T., Sugawara, M., Takekuma, Y., Association of the ward pharmacy service with active implementation of therapeutic drug monitoring for vancomycin and teicoplanin—an epidemiological surveillance study using Japanese large health insurance claims database, J Pharm Health Care Sci, 6, 18, 2020. https://doi.org/10.1186/s40780-020-00174-8
77. Nashimoto S., Takekawa Y., Takekuma Y., Sugawara M., Sato Y., Drug metabolism and pharmacokinetics transport via Niemann-Pick C1 Like 1 contributes to the intestinal absorption of ubiquinone, Drug Metab Pharmacokinet, 35, 527-533, 2020. https://doi.org/10.1016/j.dmpk.2020.08.002
76. Imai, S., Momo, K., Kashiwagi, H., Miyai, T., Sugawara, M., Takekuma, Y., Nonsteroidal anti-inflammatory drugs use in patients with chronic kidney disease are often prescribed from different clinicians than those who diagnosed them, Pharmacoepidemiol Drug Saf, 29(8), 873-880,2020. https://doi.org/10.1002/pds.5027.
75. Imai, S., Takekuma, Y., Kashiwagi, H., Miyai, T., Kobayashi, M., Iseki, K., Sugawara, M., Validation of the usefulness of artificial neural networks for risk prediction of adverse drug reactions used for individual patients in clinical practice, PLoS One, 15(7), e0236789, 2020. https://doi.org/10.1371/journal.pone.0236789
74. Sato, Y., Joumura T., Takekuma, Y., Sugawara, M., Transfer of orally administered hyaluronan to the lymph, Eur J Pharm Biopharm, 154, 210-213, 2020. https://doi.org/10.1016/j.ejpb.2020.07.007
73. Kadomura, S., Takekuma, Y., Imai, S., Kashiwagi, H., Kawamoto, K., Itoh, T., Sugawara, M., Interaction between piperacillin/tazobactam and warfarin: a single-center retrospective single-arm cohort study, BPB Reports, 3(2), 65-69, 2020.
72. Tanaka, H., Hiraga, H., Takekuma, Y., Harabayashi, T., Nagamori, S., Endo, M., Sugawara M., Possibility for dose optimization of pazopanib from its plasma concentration in Japanese patients with cancer, Biol pharm bull, 43, 762-766, 2020. doi: 10.1248/bpb.b19-00560.
71. Sasaki, M., Aoyama, T., Sugawara, M., Takekuma, Y., Influence of gastrointestinal activity on the absorption of nilotinib, Drug Metab Pharmacokinet, 35, 102-110, 2020. doi: 10.1016/j.dmpk.2019.08.006.
70. Sato, Y., Yokoyama, S., Yamaki, Y., Nishimura, Y., Miyashita, M., Maruyama, S., Takekuma, Y., Sugawara, M., Enhancement of intestinal absorption of coenzyme Q10 using emulsions containing oleyl polyethylene acetic acids., Eur J Pharm Sci, 142, 105144, 2020.doi: 10.1016/j.ejps.2019.105144.
69. Imai, S.,Takekuma, Y., Miyai, T., Sugawara, M., A new algorithm optimized for initial dose settings of vancomycin using machine learning, Biol pharm bull, 43, 188-193, 2020. doi: 10.1248/bpb.b19-00729.
68. Imai, S., Kaburaki, S., Miyai, T., Kashiwagi, H., Sugawara, M., Takekuma, Y., Comparison of predictive performance of drug dose settings using renal function estimation equations based on the Japanese population: a preliminary retrospective study using vancomycin dosing data,BPB Reports, 2(5), 80-85, 2019.
67. Aoyama, T., Shibayama, Y., Furukawa, T., Sugawara, M., Takakuma, Y., Continuous cytostatic effects of BCR-ABL tyrosine kinase inhibitors (TKIs) after washout in human leukemic K562 cells, Biol Pharm Bull., 42, 1805-1813, 2019. doi: 10.1248/bpb.b19-00185.
66. Kadomura, S., Takekuma, Y., Sato, Y., Sumi, M., Kawamoto, K., Itoh, T., Sugawara, M., Higher incidence of acute kidney injury in patients treated with piperacillin/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study, Journal of Pharmaceutical Health Care and Sciences, 5 (13), doi: 10.1186/s40780-019-0142-6, 2019.
65. Kaburaki, S., Yoshimura, E., Kojima, N., Ueno, H., Sugawara, M., Takekuma,
Y., Improvement of renal function estimation equations for elderly Japanese
people, Health Science Reports, e85. DOI: 10.1002/hsr2.85, 2018
64. Sato Y., Joumura T., Nashimoto S., Yokoyama S., Takekuma Y., Yoshida
H., Sugawara M., Enhancement of lymphatic transport of lutein by oral administration
of a solid dispersion and a self-microemulsifying drug delivery system.
, Eur. J. Pharm. Biopharm., 127, 171-176, 2018. doi: 10.1016/j.ejpb.2018.02.013.
63. Nashimoto S., Sato Y., Takekuma Y., Sugawara M., Inhibitory effect
of ezetimibe can be prevented by an administration interval of 4 h between
α-tocopherol and ezetimibe. , Biopharm. Drug Dispos., 38, 280-289, 2017.
doi: 10.1002/bdd.2059.
62. Takekawa Y., Sato Y., Yamaki Y., Imai M., Noto K., Sumi M., Takekuma
Y., Iseki K., Sugawara M., An Approach to Improve Intestinal Absorption
of Poorly Absorbed Water-Insoluble Components via Niemann-Pick C1-Like
1, Biol Pharm Bull 39 (3), 301-307, 2016.doi: 10.1248/bpb.b15-00359.
61. Tazawa Y., Shigematsu A., Kasashi K., Sugita J., Endo T., Kondo T.,
Teshima T., Iseki K., Sugawara M., Takekuma Y., Pharmacokinetics and dose
adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide
and total body irradiation regimen before allogeneic hematopoietic stem
cell transplantation , Journal of Pharmaceutical Health Care and Sciences
(2016) 2:18 doi: 10.1186/s40780-016-0052-9
60. Tazawa Y, Usukubo I, Takada K, Takekuma Y, Shibayama Y, Sugawara M.,
Schedule-dependent cytotoxicity of Etoposide and cyclophosphamide in P-glycoprotein-expressing
human leukemic K-562 cells, Biol Pharm Bull. 37(8), 1323-1329, 2014
59. Sato Y, Mutoh H, Suzuki M, Takekuma Y, Iseki K, Sugawara M., Emulsification
using highly hydrophilic surfactants improves the absorption of orally
administered coenzyme Q10., Biol Pharm Bull. 36(12), 2012-2017, 2013
58. Sato Y., Kondo Y., Sumi M., Takekuma Y., Sugawara M., Intracellular
uptake mechanism of lutein in retinal pigment epithelial cells, J Pharm Pharm Sci. 16(3):494-501, 2013
57. Tazawa Y., Matsumura K., Takekuma Y., Sugawara M., Schedule-Dependent
Cytotoxicity of Etoposide (VP-16) and Cyclophosphamide in Leukemia Cell
Line K-562, Biol Pharm Bull. 35(7), 1132-1136, 2012
56. Matsubara K., Asari M., Suno M., Awaya T., Sugawara M., Omura T., Yamamoto
J., Maseda C., Tasaki Y., Shimizu K., Estimation of the duration after
methamphetamine injection using a pharmacokinetic model in suspects who
caused fatal traffic accidents, Legal Medicine 14(4), 191-196 (2012 July)
55. Wakayama K., Fukai M., Yamashita K., Kimura T., Hirokata G., Shibasaki
S., Fukumori D., Haga S., Sugawara M., Suzuki T., Taniguchi M., Shimamura
T., Furukawa H., Ozaki M., Kamiyama T., Todo S., Successful transplantation
of rat hearts subjected to extended cold preservation with a novel preservation
solution, Transplant International 25(6), 696-706 (2012 June)
54. Sato Y., Suzuki R., Kobayashi M., Itagaki S., Hirano T., Noda T., Mizuno
S., Sugawara M., Iseki K., Involvement of cholesterol membrane transporter
Niemann-Pick C1-Like 1 in the intestinal absorption of lutein, J. Pharm. Pharmaceu. Sci. 15(2), 256-264 (2012, April)
53. Takekuma Y., Yagisawa K., Sugawara M., Mutual inhibition between carvedilol
enantiomers during racemate glucuronidation mediated by human liver and
intestinal microsomes., Biol Pharm Bull. 35(2), 151-63, 2012
52. Sato Y., Itagaki S., Oikawa S., Ogura J., Kobayashi M., Hirano T.,
Sugawara M., Iseki K., Protective effect of soy isoflavone genistein on
ischemia-reperfusion in the rat small intestine, Biol. Pharm. Bull. 34(9), 1448-1454 (2011 September)
51. Shibayama Y., Iwashita Y., Yoshikawa Y., Kondo T., Ikeda R., Takeda
Y., Osada T., Sugawara M., Yamada K., Iseki K., Effect of 5-fluorouracil
treatment on SN-38 absorption from intestine in rats, Biol. Pharm. Bull. 34(9), 1418-1425 (2011 September)
50. Sato Y., Kobayashi M., Itagaki S., Hirano T., Noda T., Mizuno S., Sugawara
M., Iseki K., Protective effect of lutein after ischemia-reperfusion in
the small intestine, Food Chem., 127, 893-898 (2011 August)
49. Sato Y., Kobayashi M., Itagaki S., Hirano T., Noda T., Mizuno S., Sugawara
M., Iseki K., Pharmacokinetic properties of lutein emulsion after oral
administration to rats and effect of food intake of plasma concentration
of lutein, Biopharm. Drug Dispos., 32, 151-158 (2011 April)
48. Shibayama Y., Nakano K., Maeda H., Taguchi M., Ikeda R., Sugawara.
M., Iseki K., Takeda Y., Yamada K., Multidrug resistance Protein 2 Implicates
Anticancer Drug-Resistance to Sorafenib, Biol. Pharm. Bull. 34(3) 433-435 (2011 March)
47. Sato Y., Itagaki S., Kurokawa T., Ogura J., Kobayashi M., Hirano T.,
Sugawara M., Iseki K., In vitro and in vivo antioxidant properties of chlorogenic
acid and caffeic acid, Int. J. Pharm. 403(1-2), 136-138 (2011 January)
46. Komatsu M., Takahata M., Sugawara M., Takekuma Y., Kato T., Ito M.,
Abe Y., Irie T., Iwasaki N., Minami A., Penetration of Linezolid into Rabbit
Intervertebral Discs and Surrounding Tissues, European spine journal, 19(12), 2149-2155, 2010
45. Yamamoto T., Sugawara M., Kikukawa T., Miyauchi S., Yamaguchi M., Tero
A., Takagi S., Nakagaki T., Kinekic study of anti-viral ribavirin uptake
mediated by hCNT3 and hENT1 in Xenopus leavis oocytes, Biophys. Chem. 147, 59-65 (2010 January)
44. Kashiwagi H., Yamazaki K., Takekuma Y., Ganapathy V., Sugawara M.,
Regulatory mechanisms of SNAT2, an amino acid transporter, in L6 rat skeletal
muscle cells by insulin, osmotic shock and amino acid deprivation, Amino Acids. 36 (2), 219-230, 2009
43. Itagaki S., Ochiai A., Kobayashi M., Sugawara M., Hirano T., Iseki
K., Interaction of coenzyme Q10 with the intestinal drug transporter p-glycoprotein,
J. Agric. Food Chem. 56 (16), 6923-6927 (2008 July)
42. Itagaki S., Chiba M., Kobayashi M., Sugawara M., Kobayashi M., Hirano
T., Iseki K., Functional analysis of phenolsulfophthalein transport system
in Long-Evans Cinnamon rats, Biochim. Biophys. Acta 1178 (1), 270-275 (2008 January)
41. Takekuma, Y., Takenaka, T., Yamazaki, K., Ueno, K., Sugawara, M., Stereoselective
Metabolism of Racemic Carvedilol by UGT1A1 and UGT2B7, and Effects of Mutation
of these Enzymes on Glucuronidation Activity, Bio pharm Bull. 30 (11), 2146-2153, 2007
40. Takekuma, Y., Kakiuchi, H., Yamazaki, K., Miyauchi, S., Kikukawa, T.,
Kamo, N., Ganapathy, V., Sugawara, M., Difference between Pharmacokinetics
of Mycophenolic acid (MPA) in Rats and that in Humans is caused by Different
affinities of MRP2 to a glucuronized form, J Pharm Pharmaceut Sci. 10(1), 71-85, 2007
39. Takekuma, Y., Takenaka, T., Kiyokawa, M., Yamazaki, K., Okamoto, H.,
Kitabatake, A., Tsutsui, H., Sugawara, M., Evaluation of effects of polymorphism
for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic
analysis, Bio pharm Bull. 30 (3), 537-542, 2007
38. Yamamoto, T., Kuniki, K., Takekuma, Y., Hirano, T., Iseki, K., and
Sugawara, M. , Ribavirin uptake by cultured human choriocarcinoma (BeWo)
cells and Xenopus laevis oocytes expressing recombinant plasma membrane
human nucleoside transporters., Eur J Pharmacol. 557 (1), 1-8, 2007
37. Takekuma, Y., Takenaka, T., Kiyokawa, M., Yamazaki, K., Okamoto, H.,
Kitabatake, A., Tsutsui, H., Sugawara, M., Contribution of Polymorphisms
in UDP-Glucuronosyltransferase and CYP2D6 to the Individual Variation in
Disposition of Carvedilol, J Pharm Pharmaceut Sci.9 (1), 101-112, 2006
36. Sugawara M., Kadomura S., He, X., Takekuma Y., Kohri N., Miyazaki K.,
The use of an in vitro dissolution and absorption system to evaluate oral
absorption of two weak bases in pH independent controlled-release formulations,
Eur. J. Pharm. Sci. 26, 1-8, 2005
35. Sugawara M., Mochizuki T., Takekuma Y., Miyazaki M, Structure-affinity
relationship in the interactions of human organic anion transporter 1 with
caffeine, theophylline, theobromine and their metabolites,Biochim Biophys Acta 1714, 85-92, 2005
34. Itagaki S., Shimamoto S., Sugawara M., Kobayashi M., Miyazaki K., Hirano
T., Iseki K., Phenolsulfonphthalein transport by potential-sensitive urate
transport system, Eur. J. Pharm. 518 (2-3), 83-89 (2005 August)
33. Itagaki S., Chiba M., Shimamoto S., Sugawara M., Kobayashi M., Miyazaki
K., Hirano T., Iseki K., Characterization of secretory intestinal transport
of phenolsulfonphthalein, Drug Metab. Pharmacokin. 20 (1), 72-78 (2005 February)
32. Gopal E., Fei Y.-J., Sugawara M., Miyauchi S., Zhuang L., Martin P.,
Smith S. B., Prasad P. D., Ganapathy V., Expression of slc5a8 in kidney
and its role in Na+-coupled transport of lactate, J. Biol. Chem. 279 (43), 44522-44532, 2004, August)
31. Itagaki S., Shimamoto S., Hirano T., Iseki K., Sugawara M., Nishimura
S., Fujimoto M., Kobayashi M., Miyazaki K., Comparison of urinary excretion
of phenolsulfonphthalein in an animal model for Wilson's disease (Long-Evans
Cinnamon rats) with that in normal Wistar rats: Involvement of primary
active organic anion transporter, J. Pharm. Pharmaceut. Sci. 7 (2), 227-234 (2004, July)
30. He, X., Sugawara M., Takekuma Y., Miyazaki K., Absorption of ester
prodrugs in Caco-2 and rat intestine models, Antimicrob. Agents Chemother. 48 (7), 2604-2609, 2004
29. Kishino S., Ogawa M., Takekuma Y., Sugawara M., Shimamura S., Furukawa
H., Todo S., Miyazaki K., The variability of liver graft function and urinary
6β-hydroxycortisol to cortisol ratio during liver regeneration in liver
transplant recipients, Clin. Transplantation 18, 124-129, 2004
28. Kishino S., Ogawa M., Takekuma Y., Sugawara M., Shimamura S., Furukawa
H., Todo S., Miyazaki K., The variability of liver graft function and urinary
6β-hydroxycortisol to cortisol ratio during liver regeneration in liver
transplant recipients, Clin. Transplant. 18 (2), 124-129 (2004, April)
27. Itagaki S., Sugawara M., Kobayashi M., Miyazaki K., Hirano T., Iseki
K., Comparison of the disposition behavior of organic anions in an animal
model for Wilson's disease (Long-Evans Cinnamon rats) with that in normal
Long-Evans Agouti rats, Drug Metab. Pharmacokin. 19 (2), 150-154 (2004, April)
26. He X., Kadomura S., Takekuma Y., Sugawara M., Miyazaki K., A new system
for prediction of drug absorption by using a pH-controlled Caco-2 Model:
Evaluation of pH-dependent soluble drug absorption and pH-related changes
in absorption, J. Pharm. Sci. 93 (1), 71-77, 2004
25. Sugawara, M., Kato, M., Kitakubo, M., Takekuma, Y., Ganapathy, V.,
Miyazaki, K., Inhibitory effects of basic drugs on the sodium-dependent
transport of L-Alanine via System B0 in the small intestine, Drug Metabol. Pharmacokin. 18 (3), 186-193, 2003
24. Nakagawa T., Kishino S., Itoh S., Sugawara M., Miyazaki K., Differential
binding of disopyramide and warfarin enantiomers to human alpha-1-acid
glycoprotein variants, Br. J. Clin. Pharmcol. 56 (6), 664-669 (2003, December)
23. Kishino S., Takekuma Y., Sugawara M., Shimamura S., Furukawa H., Todo
S., Miyazaki K., Influence of continuous venovenous haemodiafiltration
on the pharmacokinetics of tacrolimus in liver transplant recipients with
small-for-size grafts., Clin. Transplantation 17 (5), 412-416, 2003
22. He X., Sugawara M., Kobayashi M., Takekuma Y., Miyazaki K., An in vitro
system for prediction of oral absorption of relatively water-soluble drugs
and ester prodrugs. ,Int. J. Pharm. 263, 35-44, 2003
21. Itagaki S., Sugawara M., Kobayashi M., Miyazaki K., Iseki K., Mechanism
of active secretion of phenolsulfonphthalein in the liver via mrp2 (abcc2),
an organic anion transporter, Drug Metab. Pharmacokin. 18 (4), 238-244 (2003, August)
20. Itagaki S., Sugawara M., Kobayashi M., Nishimura S., Fujimoto M., Miyazaki
K., Iseki K., Major role of organic anion transporters in the uptake of
phenolsulfonphthalein in the kidney, Eur. J. Pharmacol., 475 (1-3), 85-92 (2003, August)
19. Sugawara M., Ogawa T., Kobayashi M., Miyazaki K., Uptake of dipeptide
and β-lactam antibiotics by the basolateral membrane vesicles prepared
from rat kidney, Biochim. Biophys. Acta 1609 (1), 39-44 (2003, January)
18. Hiratsuka, M., Kishikawa, Y., Takekuma, Y., Matsuura, M., Narahara,
K., Inoue, T., Hamdy, S. I., Endo, N., Goto, J., Mizugaki, M., Genotyping
of the N-acetyltransferase2 Polymorphism in the Prediction of Adverse Drug
Reactions to Isoniazid in Japanese Patients, Drug Metabol. Pharmacokin. 17 (4), 357-362, 2002
17. Kishino, S., Nomura, A., Itoh, S., Nakagawa, T., Takekuma, Y., Sugawara,
M., Furukawa, H., Todo, S., Miyazaki, K., Age- and gender-related differences
in carbohydrate concentrations of alpha1-acid glycoprotein variants and
the effects of glycoforms on their drug-binding capacities, Eur. J. Clin. Pharmacol. 58 (9), 621-628, 2002
16. Kishino, S., Takekuma, Y., Sugawara, M., Shimamura, T., Furukawa, H.,
Todo, S., Miyazaki, K., Liquid chromatographic method for the determination
of ganciclovir and/or acyclovir in human plasma using pulsed amperometric
detection, J. Chromatogr. B 780 (2), 289-294, 2002
15. Hiratsuka, M., Takekuma, Y., Endo, N., Narahara, K., Hamdy, S. I.,
Kishikawa, Y., Matsuura, M., Agatsuma, Y., Inoue, T., Mizugaki, M., Allele
and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population,
Eur. J. Clin. Pharmacol. 58 (6), 417-421, 2002
14. Sugawara M., Kurosawa M., Sakai K., Kobayashi M., Iseki K., Miyazaki
K., Ionic strength has a greater effect than does transmembrane electric
potential difference on permeation of tryptamine and indoleacetic acid
across Caco-2 cells, Biochim. Biophys. Acta 1564 (1), 149-155 (2002, August)
13. Nakanishi T., Sugawara M., Huang W., Martindale R. G., Leibach F. H.,
Ganapathy M. E., Prasad P. D., Ganapathy V., Structure, function, and tissue
expression pattern of human SN2, a subtype of amino acid transport system
N, Biochem. Biophys. Res. Commun. 281 (5), 1343-1348, 2001
12. Ling R., Bridges C. C., Sugawara M., Fujita T., Leibach F. H., Prasad
P. D., Ganapathy V., Involvement of transporter recruitment as well as
gene expression in the substrate-induced adaptive regulation of amino acid
transport system A, Biochim. Biophys. Acta 1512 (1), 15-21, 2001
11. Hatanaka T., Huang W., Ling R., Prasad P. D., Sugawara M., Leibach
F. H., Ganapathy V., Evidence for the transport of neutral as well as cationic
amino acids by ATA3, a novel and liver-specific subtype of amino acid transport
system A, Biochim. Biophys. Acta 1510 (1-2), 10-17, 2001
10. Kishino, S., Koshinami, Y., Hosoi, T., Suda, N., Takekuma, Y., Gandoh,
S., Furukawa, H., Todo, S., Miyazaki, K., Effective fluconazole therapy
for liver transplant recipients during continuous hemodiafiltration, Ther. Drug. Monit. 23 (1), 4-8, 2001
9. Kobayashi M., Sada N., Sugawara M., Iseki K., Miyazaki K., Development
of a new system for prediction of drug absorption that takes into account
drug dissolution and pH change in the gastro-intestinal tract, Int. J. Pharm. 221 (1-2), 87-94 (2001, June)
8. Nakanishi T., Kekuda R., Fei Y.-J., Hatanaka T., Sugawara M., Martindale
R. G., Leibach F. H., Prasad P. D., Ganapathy V., Cloning and functional
characterization of a new subtype of the amino acid transport system N,
Am. J. Physiol. Cell Physiol. 281 (6), C1757-C1768, 2001
7. Ganapathy M. E., Huang W., Rajan D. P., Carter A. L., Sugawara M., Iseki
K., Leibach F. H., Ganapathy V., β-Lactam antibiotics as substrates for
OCTN2, an organic cation/carnitine transporter, J. Biol. Chem. 275 (3), 1699-1707, 2000
6. Sugawara M., Huang W., Fei Y.-J., Leibach F. H., Ganapathy V., Ganapathy
M. E., Transport of valganciclovir, a ganciclovir prodrug, via peptide
transporters PEPT1 and PEPT2, J. Pharm. Sci. 89 (6), 781-789, 2000
5. Sugawara M., Nakanishi T., Fei Y.-J., Martindale R. G., Ganapathy M.
E., Leibach F. H., Ganapathy V., Structure and function of ATA3, a new
subtype of amino acid transport system A, primarily expressed in the liver
and skeletal muscle, Biochim. Biophys. Acta 1509 (1-2), 7-13, 2000
4. Fei Y.-J., Sugawara M., Nakanishi T., Huang W., Wang H., Prasad P. D.,
Leibach F. H., Ganapathy V., Primary structure, genomic organization, and
functional and electrogenic characteristics of human system N (SN1), a
Na+- and H+-coupled glutamine transporter, J. Biol. Chem. 275 (31), 23707-23717, 2000
3. Hatanaka T., Huang W., Wang H., Sugawara M., Prasad P. D., Leibach F.
H., Ganapathy V., Primary structure, functional characteristics and tissue
expression pattern of human ATA2, a subtype of amino acid transport system,
Biochim. Biophys. Acta 1467 (1), 1-6, 2000
2. Sugawara M., Nakanishi T., Fei Y.-J., Huang W., Ganapathy M. E., Leibach
F. H., Ganapathy V., Cloning of an amino acid transporter with functional
characteristics and tissue expression pattern identical to that of system
A, J. Biol. Chem. 275 (22), 16473-16477, 2000
1. Wang H., Huang W., Sugawara M., Devoe L. D., Leibach F. H., Prasad P.
D., Ganapathy V., Cloning and functional expression of ATA1, a subtype
of amino acid transporter A, from human placenta, Biochem. Biophys. Res. Commun. 273 (3), 1175-1179, 2000
原著論文（和文）
Original Articles (in Japanese)
42. 宮井貴之，今井俊吾，百 賢二，柏木 仁，佐藤夕紀，菅原 満，武隈 洋, 大規模レセプトデータベースを用いたボリコナゾールの治療薬物モニタリング実施に関する実態調査,
TDM研究 38(3), 39-48, 2021
41. 今井俊吾，難波正志，柏木 仁，佐藤夕紀，武隈 洋，菅原 満, 薬局薬剤師による「患者への聞き取り」に基づいて実施された疑義照会の実態解明と医療安全への貢献度評価
, 薬局薬学 13(1), 68-71, 2021, https://doi.org/10.32160/yakkyoku.nt.2020-0025
40. 濱野宏美，土井正剛，武隈 洋，菅原 満，一木崇宏 , レビー小体型認知症に対してリバスチグミンからの切り替えで低用量長期間ガランタミン投与が有効だった1症例
, 日本老年薬学会雑誌 2 (2), 27-34, 2019
39. 武隈 洋，森 綾子，小林正紀，山田勇磨，佐藤夕紀，鳴海克哉，古堅彩子，菅原 満, 薬学実務実習前後における薬学生のコミュニケーション分析
～RIAS（Roter method of interaction process analysis）を用いて～, 薬学雑誌 138(12),
1579-1586, 2018
38. 武隈 洋，石坂 悠，高地里佳，吉村恵理，小嶋希望，上野英文，平野卓哉，野田敏宏，熊井惠美，菅原 満, 耳鼻咽喉科領域におけるアレルギー性咳嗽症状を有する患者に対する抗アレルギー薬併用の実態調査,
薬局薬学 9(1), 159-168, 2017
37. Tanaka H., Sako M., Morioka Y., Motoshige H., Takekuma Y., Kawamoto
H., Sugawara M., Hiraga H., Simple blood sample pre-treatment to remove
DAMPA in ARCHITECT® for methotrexate, Jpn. J. TDM. 34 (1), 1-7, 2017
36. 武隈 洋，田澤佑基，臼窪一平，高田一輝，柴山良彦，重松明男，笠師久美子，豊嶋崇徳，井関 健，菅原 満, 造血幹細胞移植時の抗がん剤併用療法における投与量および薬物曝露順序の最適化,
臨床薬理の進歩 36, 142-152, 2015.06
35. 武隈 洋, 高地里佳, 石坂 悠, 佐藤夕紀, 鷲見正人, 菅原 満, 開封後のスタチン製剤の安定性に及ぼす光・温度・湿度の影響, 医療薬学
40(3)，135-146, 2014
34. 髙橋夏子、小林正紀、板垣史郎、平野 剛、武隈 洋、菅原 満、井関 健, 効果発現パターンにより抗がん薬を分類するための基礎的検討, YAKUGAKU
ZASSHI 132(6), 777-783 (2012，6月)
33. 長田貴之、柴山良彦、熊井正貴、山田武宏、笠師久美子、倉本倫之介、洲崎真吾、赤澤 茂、真栄田浩行、坂下智博、折舘伸彦、本間明宏、福田 諭、菅原 満、井関 健,
オピオイドによる難治性の嘔気とめまいに対してヒスタミンH1受容体拮抗薬とペロスピロンの併用が有効であった2症例, 医療薬学 38（1），51-55（2012，1月）
32. 高橋夏子，小林正樹，板垣史郎，平野 剛，武隈 洋，菅原 満，井関 健, 効果発現パターンにより抗がん薬を分類するための基礎的検討, 薬学雑誌
132（6），777-783，2012
31. 板垣史郎、中田千絵、平野 剛、鷹野瑠美、笠師久美子、菅原 満、高橋夏子、小林正紀、井関 健, 放射線治療に伴う口腔粘膜障害に対する予防・軽減効果が期待される物質の探索,
医療薬学 36 (9), 696-702 (2010, 9月)
30. 斎藤由起子、平野 剛、沖 洋充、笠師久美子、菅原 満、小林正樹、高橋夏子、板垣史郎、井関 健, In vitro実験系による肺がん化学療法レジメンの抗腫瘍効果の評価,
医療薬学 36 (4)，220-226（2010，4月）
29. 山﨑浩二郎、武隈 洋、西村あや子、宮本剛典、菅原 満、井関 健, 高度腎機能障害患者におけるリネゾリドの体内動態, TDM研究 26
(4), 137-141 (2009, 10月)
28. 鷹野瑠美、平野 剛、中田千絵、笠師久美子、菅原 満、小林正紀、板垣史郎、井関 健, がん化学療法に伴う口内炎の予防・改善に有効な抗酸化物質の探索,
医療薬学 35 (4), 247-253 (2009, 4月)
27. 久保田康生、小林正紀、笠師久美子、高畑むつみ、菅原 満、橋野 聡、井関 健, 多発性骨髄腫における同種造血幹細胞移植後の慢性消化管GVHDに対しベクロメタゾン腸溶性製剤を投与した症例,
医療薬学 35 (3), 213-218 (2009, 3月)
26. 山﨑浩二郎, 武隈 洋, 西村あや子，宮本剛典，菅原 満，井関 健, 高度腎機能障害患者におけるリネゾリドの体内動態, TDM研究 26
(4), 137-141, 2009
25. 三浦正義，阿知波一人，下田直彦，武隈 洋，原田 浩, 腎移植レシピエントにおけるミコフェノール酸の治療的薬物モニタリングの臨床応用 －薬物動態学および薬力学的解析を用いて－,
臨床薬理の進歩 30, 106-117, 2009.07
24. 菅原 満、山澤裕司、齋藤嘉津彦、小林道也、田中寛之、唯野貢司, MRSA感染治療におけるteicoplaninの投与設計の検討, TDM研究
25 (1), 28-36 (2008, １月)
23. 清川真美、澤口利香、須田範行、武隈 洋、菅原 満、相馬孝光、川嶋 望、筒井裕之、井関 健, 心臓血管造影剤による急性腎機能低下に対するアセチルシステインの予防効果および製剤の評価,
医療薬学 34 (1), 20-25 (2008, 1月)
22. 清川真美, 澤口利香, 須田範行, 武隈 洋, 菅原 満, 相馬孝光, 川嶋 望, 筒井裕之, 井関 健, 心臓血管造影剤による急性腎機能低下に対するアセチルシステインの予防効果および製剤の評価,
医療薬学 34 (1), 20-25, 2008
21. 久保田康生、中里恭子、須田範行、沖 洋充、菅原 満、小林道也、齊藤浩司、井関 健, 外来化学療法における服薬指導の充実のための病棟－外来間連携ツールの構築,
医療薬学 33 (2), 152-158 (2007，2月)
20. 山﨑浩二郎、武隈 洋、志賀弘康、菅原 満、小澤剛久、柴田万里子、橋本聡一、森本裕二, 神経因性疼痛に対する酢酸フレカイニドの鎮痛効果と血中濃度の関係,
ＴＤＭ研究 23 (4), 253-256 (2006, 10月)
19. 久保田康生、沖 洋充、山崎浩一、菅原 満、西村正治、井関 健, 患者の健康食品摂取状況および意識調査と健康食品データベース構築, 日本病院薬剤師会雑誌
42 (7), 927-929 (2006，7月)
18. 渡井至彦, 森田研, 三浦正義, 福澤信之, 小野武紀, 柴田武, 野々村克也, 帯金克行, 中嶋泰志, 佐々木聡, 松浦麻耶, 山崎浩二郎,
武隈洋, 小児腎移植におけるSteroid Avoidance免疫抑制法の検討, 日本小児腎不全学会雑誌 26, 242-244, 2006
17. 山﨑浩二郎, 武隈 洋, 西村あや子，宮本剛典，菅原 満，井関 健, 神経因性疼痛に対する酢酸フレカイニドの鎮痛効果と血中濃度の関係,
TDM研究 23 (4), 253-256, 2006
16. 志賀弘康、川合真次、荻野 修、菅原 満、遠藤 晃、櫻井恒太郎、宮崎勝巳, 麻薬管理の一元化を可能とした麻薬オーダリングシステムの構築と運用,
医療薬学 31 (12), 1027-1035（2005，12月）
15. 瀬戸恵介、須田範行、荻野 修、菅原 満, 外来治療センターにおける薬剤師業務, 日本病院薬剤師会雑誌 41 (11), 1407-1409（2005，11月）
14. 武隈 洋、岩井美和子、藤原俊恵、川岸 亨、熊井正貴、松浦麻耶、馬渕朋美、須田範行、宮本剛典、荻野 修、菅原 満、宮崎勝巳, 癌化学療法の調剤業務支援のためのプロトコールデータベースの構築と運用,
医療薬学 31 (7), 575-584（2005，7月）
13. 須田範行、新里利香、清川真美、金内美妃、菅原 満、郡 修徳、宮崎勝巳, 造影剤による腎機能低下の予防を目的としたアセチルシステインゼリーの調製と評価,
医療薬学 31 (5), 355-359（2005，5月）
12. 武隈 洋, 岩井美和子, 藤原俊恵, 川岸 亨, 熊井正貴, 松浦麻耶, 馬渕朋美, 須田範行, 宮本剛典, 荻野 修, 菅原 満,
宮崎勝巳, がん化学療法の調剤業務支援のためのプロトコールデータベースの構築と運用, 医療薬学 31 (7), 575-584, 2005
11. 岸野吏志, 馬渕朋美, 武隈 洋, 菅原 満, 嶋村 剛, 古川裕之, 藤堂 省, 宮崎勝巳, 生体部分肝移植患者におけるLinezolid
(Zyvoc) の体内動態, TDM研究 21 (1), 21-25, 2004
10. 須田範行、今野安大、森田 豊、中田 宏、菅原 満、宮崎正三、宮崎勝巳, 癌化学療法時に見られる口内炎発症予防を目的としたメシル酸カモスタット口腔内崩壊錠の調製と評価,
医療薬学 29 (6), 705-710（2003，6月）
9. 笠原勇太、高田陽美、小林道也、川合真次、荻野 修、菅原 満、関川 彬、宮崎勝巳, 循環器系薬剤に関する総合的な医薬品情報データベースの構築,
医療薬学 29 (2), 165-172（2003，2月）
8. 岸野吏志、越浪由加、菅原 満、丸藤 哲、古川博之、藤堂 省、宮崎勝巳, 生体肝移植患者における持続血液濾過透析（CHDF）施行時のタクロリムスの血中動態,
ＴＤＭ研究 20 (1), 24-29（2003，1月）
7. 武隈 洋, 山下恭範, 岩井美和子, 志賀弘康, 須田範行, 岸野吏志, 宮崎勝巳, 心筋保護液の安定性と使用期間の検討, 医療薬学 29
(2), 225-229, 2003
6. 武隈 洋, 志賀弘康, 山下恭範, 須田範行, 岩井美和子, 岸野吏志, 宮崎勝巳, 0.625%洗眼用イソジン液の安定性に関する検討,
医療薬学 29 (1), 62-65, 2003
5. 井藤達也、福田由布子、竹本 功、斉藤正信、松岡伸一、秦 温信、平野 剛、井関 健、菅原 満、宮崎勝巳, 胃癌患者における胃切除術後の薬物吸収動態,
臨床薬理．33 (3), 67-72（2002，3月）
4. 菅原 満、荻野 修、宮崎勝巳, ザイボックス?錠を粉砕して製した懸濁液の安定性に関する検討, 医療薬学 28 (3), 256-258（2002，5月）
3. 井藤達也、高岡和夫、竹本 功、秦 温信、井上勝一、佐々木健太郎、平野 剛、井関 健、菅原 満、宮崎勝巳, 肺癌患者における塩酸イリノテカン（CPT-11）の胸水中および心嚢液中への移行性,
臨床薬理 33 (2), 47-52（2002，2月）
2. 越浪由加, 細井 健, 武隈 洋, 小林道也, 岸野吏志, 森本祐二, 丸藤 哲, 古川裕之, 藤堂 省, 宮崎勝巳, 生体肝移植患者における持続血液濾過透析（CHDF）施行時のタクロリムス及びフルコナゾールの血中動態,
TDM研究 19 (1), 39-43, 2002
1. 井藤達也、竹本 功、秦 温信、高岡和夫、菅原 満、井関 健、宮崎勝巳, イリノテカンと活性代謝物のラクトン体・カルボキシル体およびその抱合体のHPLC同時定量法の確立, ＴＤＭ研究 17 (4), 383-389（2000，10月）